{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:51:43Z","timestamp":1792705903221,"version":"4.5.0"},"reference-count":321,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["226-2024-00012"],"award-info":[{"award-number":["226-2024-00012"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072959"],"award-info":[{"award-number":["82072959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273178"],"award-info":[{"award-number":["82273178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172688"],"award-info":[{"award-number":["82172688"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["822731781"],"award-info":[{"award-number":["822731781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR24H160001"],"award-info":[{"award-number":["LR24H160001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","award":["171132002"],"award-info":[{"award-number":["171132002"]}],"id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189544","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:04:17Z","timestamp":1769533457000},"page":"189544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics"],"prefix":"10.1016","volume":"1881","author":[{"given":"Junjie","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-023-01797-9","article-title":"Nanomaterials in tumor immunotherapy: new strategies and challenges","volume":"22","author":"Zhu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12943-025-02225-w","article-title":"Biometallic ions and derivatives: a new direction for cancer immunotherapy","volume":"24","author":"Zhao","year":"2025","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189544_bb0040","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41574-020-0398-9","article-title":"Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies","volume":"16","author":"French","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6382","key":"10.1016\/j.bbcan.2026.189544_bb0050","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-024-02214-5","article-title":"Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0065","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-023-01770-6","article-title":"Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0085","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1152\/physrev.00008.2020","article-title":"Moving immune therapy forward targeting TME","volume":"101","author":"Goliwas","year":"2021","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-022-01304-5","article-title":"Crosstalk among m(6)A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0100","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-022-01561-5","article-title":"Reprogramming the tumor microenvironment by genome editing for precision cancer therapy","volume":"21","author":"Liu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0115","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0130","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0135","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0140","first-page":"83","article-title":"Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma","volume":"2","author":"Ma","year":"2021","journal-title":"Nat. Can."},{"issue":"13","key":"10.1016\/j.bbcan.2026.189544_bb0145","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","article-title":"Osr2 functions as a biomechanical checkpoint to aggravate CD8(+) T cell exhaustion in tumor","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-020-01260-z","article-title":"Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook","volume":"19","author":"Horvath","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-020-01151-3","article-title":"Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma","volume":"19","author":"Fan","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","article-title":"Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges","volume":"17","author":"Martin","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb0175","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0180","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0185","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0190","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0195","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41423-023-00980-8","article-title":"Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy","volume":"20","author":"Gu","year":"2023","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0200","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13045-021-01218-8","article-title":"The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molcel.2017.01.023","article-title":"Comparative analysis of single-cell RNA sequencing methods","volume":"65","author":"Ziegenhain","year":"2017","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/cac2.12078","article-title":"Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy","volume":"40","author":"Ding","year":"2020","journal-title":"Cancer Commun. (Lond.)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0215","doi-asserted-by":"crossref","first-page":"10215","DOI":"10.1038\/s41467-025-64990-y","article-title":"Systematic benchmarking of imaging spatial transcriptomics platforms in FFPE tissues","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nmeth.4220","article-title":"Power analysis of single-cell RNA-sequencing experiments","volume":"14","author":"Svensson","year":"2017","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0225","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41467-020-14976-9","article-title":"Embracing the dropouts in single-cell RNA-seq analysis","volume":"11","author":"Qiu","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0230","article-title":"A comparison of deep learning-based pre-processing and clustering approaches for single-cell RNA sequencing data","volume":"23","author":"Wang","year":"2022","journal-title":"Brief. Bioinform."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-019-1906-x","article-title":"scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation","volume":"21","author":"Madissoon","year":"2019","journal-title":"Genome Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0240","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1038\/s41467-024-51728-5","article-title":"STIE: single-cell level deconvolution, convolution, and clustering in in situ capturing-based spatial transcriptomics","volume":"15","author":"Zhu","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0245","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.1038\/s41467-025-64292-3","article-title":"Systematic benchmarking of high-throughput subcellular spatial transcriptomics platforms across human tumors","volume":"16","author":"Ren","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0250","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41587-023-02086-y","article-title":"Decoder-seq enhances mRNA capture efficiency in spatial RNA sequencing","volume":"42","author":"Cao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0255","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41592-021-01391-1","article-title":"Deterministic scRNA-seq captures variation in intestinal crypt and organoid composition","volume":"19","author":"Bues","year":"2022","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb0260","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s41592-018-0229-2","article-title":"Deep generative modeling for single-cell transcriptomics","volume":"15","author":"Lopez","year":"2018","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-24-1472","article-title":"SpatialDeX is a reference-free method for cell-type deconvolution of spatial transcriptomics data in solid Tumors","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0270","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41467-018-08205-7","article-title":"Deconvolution of single-cell multi-omics layers reveals regulatory heterogeneity","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb0275","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41592-024-02408-1","article-title":"Mapping cellular interactions from spatially resolved transcriptomics data","volume":"21","author":"Zhu","year":"2024","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0280","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12916-025-03889-3","article-title":"Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer","volume":"23","author":"Xie","year":"2025","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0285","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ccell.2025.03.011","article-title":"Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures","volume":"43","author":"Tang","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0290","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1038\/s41467-025-65421-8","article-title":"Single-cell and spatial transcriptomics implicate a prognostic function of tertiary lymphoid structures in gastric cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0295","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s12967-024-05307-3","article-title":"Progress of single-cell RNA sequencing combined with spatial transcriptomics in tumour microenvironment and treatment of pancreatic cancer","volume":"22","author":"Zhu","year":"2024","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0310","first-page":"924","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Can."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0315","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2023.01.010","article-title":"Spatial profiling technologies illuminate the tumor microenvironment","volume":"41","author":"Elhanani","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0320","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0325","doi-asserted-by":"crossref","first-page":"10259","DOI":"10.1038\/s41467-024-54710-3","article-title":"Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients","volume":"15","author":"Feng","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0330","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13073-025-01553-2","article-title":"Spatial-reprogramming derived GPNMB(+) macrophages interact with COL6A3(+) fibroblasts to enhance vascular fibrosis in glioblastoma","volume":"17","author":"Du","year":"2025","journal-title":"Genome Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0335","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0340","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1038\/s41467-025-59341-w","article-title":"Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted CD4(+) T cells in head and neck cancer","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0345","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1038\/s41467-024-53262-w","article-title":"Spatial dynamics of CD39(+)CD8(+) exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer","volume":"15","author":"Tanoue","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0350","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189544_bb0355","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.1016\/j.cell.2025.09.021","article-title":"CRATER tumor niches facilitate CD8(+) T cell engagement and correspond with immunotherapy success","volume":"188","author":"Ludin","year":"2025","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0360","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ccell.2023.03.015","article-title":"Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma","volume":"41","author":"Gaglia","year":"2023","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189544_bb0365","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169314","article-title":"Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors","volume":"133","author":"Sun","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb0370","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Espinosa-Carrasco","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0375","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s12964-025-02444-0","article-title":"Blocking CCR1(+) macrophages overcomes resistance to immune checkpoint inhibitors in melanoma","volume":"23","author":"Su","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189544_bb0380","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-025-06056-2","article-title":"CA9+ cancer-associated fibroblasts cooperate with SPP1+ tumor-associated macrophages driving immune resistance in triple-negative breast cancer","author":"Ma","year":"2026","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb0385","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011319","article-title":"Malevolent alliance of MYBL2(hi) cancer stem cell and SPP1+ macrophage confers resistance to neoadjuvant immunotherapy in bladder cancer","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"7791","key":"10.1016\/j.bbcan.2026.189544_bb0390","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0395","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0400","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0410","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb0415","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","article-title":"The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition","volume":"32","author":"Loi","year":"2021","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb0420","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S2468-1253(24)00091-8","article-title":"Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis","volume":"9","author":"Wankhede","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0425","first-page":"1123","article-title":"Single-cell meta-analyses reveal responses of tumor-reactive CXCL13(+) T cells to immune-checkpoint blockade","volume":"3","author":"Liu","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189544_bb0430","first-page":"OF1","article-title":"Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype","author":"Pozniak","year":"2025","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0435","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0440","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ccell.2025.01.007","article-title":"Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer","volume":"43","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"issue":"7851","key":"10.1016\/j.bbcan.2026.189544_bb0445","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","article-title":"CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours","volume":"591","author":"Zappasodi","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0450","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.bbcan.2026.189544_bb0455","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0460","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0465","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1038\/s41467-023-42332-0","article-title":"The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0470","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41467-023-38605-3","article-title":"ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189544_bb0475","article-title":"Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0480","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"issue":"16","key":"10.1016\/j.bbcan.2026.189544_bb0485","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","article-title":"LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity","volume":"187","author":"Ngiow","year":"2024","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0490","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0495","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","article-title":"Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0500","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0510","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.immuni.2024.08.003","article-title":"PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8(+) T cell ferroptosis","volume":"57","author":"Ping","year":"2024","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0515","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.immuni.2023.07.015","article-title":"CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma","volume":"56","author":"Chen","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0520","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","article-title":"Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy","volume":"12","author":"Abbas","year":"2021","journal-title":"Nat. Commun."},{"issue":"83","key":"10.1016\/j.bbcan.2026.189544_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6173","article-title":"PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance","volume":"8","author":"van Gulijk","year":"2023","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0530","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41590-021-00958-6","article-title":"Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy","volume":"22","author":"Eschweiler","year":"2021","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0535","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","article-title":"Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade","volume":"41","author":"Pai","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0540","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0545","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ccell.2024.05.013","article-title":"Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy","volume":"42","author":"Geels","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12943-023-01908-6","article-title":"A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state","volume":"22","author":"Van Lint","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0555","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0560","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0565","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0570","first-page":"239","article-title":"Linking macrophage metabolism to function in the tumor microenvironment","volume":"6","author":"Jin","year":"2025","journal-title":"Nat. Can."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0575","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-023-00846-8","article-title":"Therapeutic targeting of the functionally elusive TAM receptor family","volume":"23","author":"Miao","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb0580","first-page":"1188","article-title":"Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0585","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0590","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0595","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.7150\/thno.109097","article-title":"Spatially segregated APOE(+) macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma","volume":"15","author":"Ge","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0600","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-025-02352-4","article-title":"Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors","volume":"24","author":"Senent","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0605","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008094","article-title":"Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0610","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007441","article-title":"C1q(+) tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0615","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0620","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination Immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189544_bb0625","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","article-title":"In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0630","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41423-018-0027-x","article-title":"Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"7957","key":"10.1016\/j.bbcan.2026.189544_bb0635","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","article-title":"Antibodies against endogenous retroviruses promote lung cancer immunotherapy","volume":"616","author":"Ng","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0640","first-page":"625","article-title":"A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma","volume":"5","author":"Roland","year":"2024","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0645","article-title":"Predicting patient outcomes after treatment with immune checkpoint blockade: a review of biomarkers derived from diverse data modalities","volume":"4","author":"Liu","year":"2024","journal-title":"Cell Genom."},{"key":"10.1016\/j.bbcan.2026.189544_bb0650","article-title":"A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer","author":"Liu","year":"2025","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189544_bb0655","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.7150\/thno.44871","article-title":"CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"7980","key":"10.1016\/j.bbcan.2026.189544_bb0660","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb0665","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41591-022-02095-5","article-title":"IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Taylor","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0670","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-024-01980-6","article-title":"Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189544_bb0675","first-page":"63","article-title":"NK cell-based tumor immunotherapy","volume":"31","author":"Zhang","year":"2024","journal-title":"Bioact. Mater."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb0680","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0685","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","article-title":"MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189544_bb0690","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0695","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","article-title":"The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade","volume":"55","author":"Cucolo","year":"2022","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0700","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1158\/2159-8290.CD-24-1390","article-title":"Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade","volume":"15","author":"Jiang","year":"2025","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0705","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2159-8290.CD-22-0686","article-title":"Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma","volume":"13","author":"Chow","year":"2023","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0710","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","article-title":"IGSF8 is an innate immune checkpoint and cancer immunotherapy target","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189544_bb0715","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/0008-5472.CAN-15-1502","article-title":"Plasticity beyond cancer cells and the \u201cimmunosuppressive switch\u201d","volume":"75","author":"Granot","year":"2015","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189544_bb0720","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.22.02144","article-title":"Novel genetic subtypes of urothelial carcinoma with differential outcomes on immune checkpoint blockade","volume":"41","author":"Sarfaty","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0725","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","article-title":"Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma","volume":"6","author":"Lalani","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0730","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181671","article-title":"Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge","volume":"135","author":"Qin","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0735","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-023-02552-z","article-title":"Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2\/PGE2\/IDO1 Axis","volume":"130","author":"Ouyang","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb0740","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013079","article-title":"PINK1 dysfunction in hepatocellular carcinoma fosters immune evasion and disease progression by promoting neutrophil infiltration","volume":"13","author":"Gu","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0745","first-page":"421","article-title":"Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer","volume":"20","author":"Feng","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0750","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2024.02.009","article-title":"CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma","volume":"81","author":"Xie","year":"2024","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0755","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002305","article-title":"Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"22","key":"10.1016\/j.bbcan.2026.189544_bb0760","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1158\/0008-5472.CAN-24-4962","article-title":"SPP1+ neutrophils mediate resistance to immune checkpoint blockade in BAP1-inactivated Tumors","volume":"85","author":"Shi","year":"2025","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0765","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41419-025-08064-3","article-title":"Claudin-7 deficiency induces metabolic reprogramming of neutrophils in the colorectal cancer microenvironment","volume":"16","author":"Liang","year":"2025","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0770","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/hep.32383","article-title":"KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration","volume":"76","author":"Wang","year":"2022","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb0775","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ccell.2025.07.007","article-title":"CHI3L3(+) immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases","volume":"43","author":"Shi","year":"2025","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb0780","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1016\/j.immuni.2023.11.002","article-title":"The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer","volume":"56","author":"Taifour","year":"2023","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0785","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40164-022-00345-3","article-title":"The role of neutrophil extracellular traps in cancer progression, metastasis and therapy","volume":"11","author":"Chen","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0790","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241957","article-title":"MYO1F in neutrophils is required for the response to immune checkpoint blockade therapy","volume":"222","author":"Qu","year":"2025","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0795","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0800","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/1078-0432.CCR-19-2625","article-title":"Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models","volume":"26","author":"Greene","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0805","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008979","article-title":"Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors","volume":"13","author":"Xiong","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb0810","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","article-title":"Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma","volume":"130","author":"Loeuillard","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0815","first-page":"803","article-title":"Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression","volume":"2","author":"Lopez-Bujanda","year":"2021","journal-title":"Nat. Can."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0820","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.ymthe.2025.02.002","article-title":"Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8\/CXCR2 signaling","volume":"33","author":"Kwong","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0825","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1038\/s41467-022-34871-9","article-title":"ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0830","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154127","article-title":"Cell communication network factor 4 promotes tumor-induced immunosuppression in melanoma","volume":"23","author":"Fernandez","year":"2022","journal-title":"EMBO Rep."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb0835","article-title":"PPP1R15A-expressing monocytic MDSCs promote immunosuppressive liver microenvironment in fibrosis-associated hepatocellular carcinoma","volume":"6","author":"Liu","year":"2024","journal-title":"JHEP Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0840","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/2326-6066.CIR-20-0433","article-title":"Targeting PIM1-mediated metabolism in myeloid suppressor cells to treat cancer","volume":"9","author":"Xin","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"40","key":"10.1016\/j.bbcan.2026.189544_bb0845","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1073\/pnas.1800695115","article-title":"Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers","volume":"115","author":"Feng","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189544_bb0850","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1158\/0008-5472.CAN-21-1148","article-title":"Myeloid-derived suppressive cell expansion promotes melanoma growth and autoimmunity by inhibiting CD40\/IL27 regulation in macrophages","volume":"81","author":"Valencia","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb0855","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2021","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb0860","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb0865","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0870","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","article-title":"Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer","volume":"12","author":"McAndrews","year":"2022","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb0875","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/1078-0432.CCR-21-3570","article-title":"Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer","volume":"28","author":"Obradovic","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189544_bb0880","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0885","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0890","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","article-title":"Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy","volume":"78","author":"Liu","year":"2023","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0895","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.cmet.2024.05.013","article-title":"Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer","volume":"36","author":"Jiang","year":"2024","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0900","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/gutjnl-2020-322924","article-title":"Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity","volume":"71","author":"Huang","year":"2022","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0905","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41571-019-0181-9","article-title":"Vessel co-option in cancer","volume":"16","author":"Kuczynski","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb0910","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0915","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0920","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12943-024-02221-6","article-title":"Unveiling the immunomodulatory dance: endothelial cells\u2019 function and their role in non-small cell lung cancer","volume":"24","author":"Daum","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0925","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0930","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell Death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb0935","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7150\/thno.65828","article-title":"Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells","volume":"12","author":"Tu","year":"2022","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb0940","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.immuni.2024.09.003","article-title":"T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels","volume":"57","author":"Messmer","year":"2024","journal-title":"Immunity"},{"issue":"30","key":"10.1016\/j.bbcan.2026.189544_bb0945","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404778121","article-title":"Metformin synergizes with PD-1 blockade to promote normalization of tumor vessels via CD8T cells and IFNgamma","volume":"121","author":"Tokumasu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb0950","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0955","article-title":"Normalizing the microenvironment overcomes vessel compression and resistance to Nano-immunotherapy in breast Cancer lung metastasis","volume":"8","author":"Mpekris","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb0960","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/neuonc\/noab181","article-title":"ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma","volume":"24","author":"Huang","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0965","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0970","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0975","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0980","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb0985","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0990","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13073-023-01218-y","article-title":"Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence","volume":"15","author":"Zhang","year":"2023","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb0995","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI127515","article-title":"Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy","volume":"130","author":"Sharma","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb1000","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155148","article-title":"Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-beta signaling enables PD-L1-mediated tumor eradication","volume":"132","author":"Horn","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb1005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb1010","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1158\/0008-5472.CAN-23-1418","article-title":"Integration of pan-cancer single-cell and spatial transcriptomics reveals stromal cell features and therapeutic targets in tumor microenvironment","volume":"84","author":"Du","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12916-022-02670-0","article-title":"Tumor PKCdelta instigates immune exclusion in EGFR-mutated non-small cell lung cancer","volume":"20","author":"Zuo","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","article-title":"Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Pei","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189544_bb1025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.immunol.26.021607.090316","article-title":"Interleukin-21: basic biology and implications for cancer and autoimmunity","volume":"26","author":"Spolski","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189544_bb1030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1035","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/s41467-023-37727-y","article-title":"Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer","volume":"14","author":"Palakurthi","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","article-title":"PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies","volume":"23","author":"Jin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb1045","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cmet.2024.03.015","article-title":"QDPR deficiency drives immune suppression in pancreatic cancer","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb1050","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","article-title":"Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy","volume":"27","author":"Cascone","year":"2018","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb1055","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb1065","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-15-1275","article-title":"Overcoming antigen escape with CAR T-cell therapy","volume":"5","author":"Jackson","year":"2015","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb1070","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121606","article-title":"Recent advances in CAR-based solid tumor immunotherapy","volume":"12","author":"Shin","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12943-022-01669-8","article-title":"Tumor buster - where will the CAR-T cell therapy \u2018missile\u2019 go?","volume":"21","author":"Qu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb1090","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6230","key":"10.1016\/j.bbcan.2026.189544_bb1100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189544_bb1115","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb1120","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","article-title":"Tumor-infiltrating lymphocytes: a new hope","volume":"42","author":"Sarnaik","year":"2024","journal-title":"Cancer Cell"},{"issue":"92","key":"10.1016\/j.bbcan.2026.189544_bb1125","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg7995","article-title":"Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma","volume":"9","author":"Barras","year":"2024","journal-title":"Sci. Immunol."},{"issue":"6522","key":"10.1016\/j.bbcan.2026.189544_bb1130","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb1135","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.immuni.2024.08.014","article-title":"Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma","volume":"57","author":"Chiffelle","year":"2024","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.bbcan.2026.189544_bb1140","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in anti-PD-1 naive and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb1145","first-page":"801","article-title":"Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy","volume":"6","author":"Wang","year":"2025","journal-title":"Nat. Can."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011066","article-title":"CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion","volume":"13","author":"Rossetti","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"8011","key":"10.1016\/j.bbcan.2026.189544_bb1155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","article-title":"PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function","volume":"629","author":"Morotti","year":"2024","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189544_bb1160","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/1078-0432.CCR-12-1177","article-title":"Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients","volume":"18","author":"Radvanyi","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb1165","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","article-title":"Neoantigen-specific stem cell memory-like CD4(+) T cells mediate CD8(+) T cell-dependent immunotherapy of MHC class II-negative solid tumors","volume":"24","author":"Brightman","year":"2023","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb1170","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.4049\/jimmunol.1101244","article-title":"CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation","volume":"187","author":"Qui","year":"2011","journal-title":"J. Immunol."},{"issue":"7967","key":"10.1016\/j.bbcan.2026.189544_bb1175","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"issue":"46","key":"10.1016\/j.bbcan.2026.189544_bb1180","article-title":"TIL therapy in lung cancer: current progress and perspectives","volume":"11","author":"Hu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189544_bb1185","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb1190","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189544_bb1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104614","article-title":"Patient-derived melanoma organoid models facilitate the assessment of immunotherapies","volume":"92","author":"Ou","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189544_bb1200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb1205","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.trecan.2025.08.002","article-title":"Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps","volume":"11","author":"Navarro Rodrigo","year":"2025","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb1215","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1220","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","article-title":"Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T","volume":"22","author":"Liu","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb1225","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1230","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41467-025-56547-w","article-title":"Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen","volume":"16","author":"Chih","year":"2025","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.bbcan.2026.189544_bb1235","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189544_bb1240","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb1245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb1250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008375","article-title":"EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb1255","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb1260","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189544_bb1265","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.bbcan.2026.189544_bb1270","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10299","key":"10.1016\/j.bbcan.2026.189544_bb1275","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"10416","key":"10.1016\/j.bbcan.2026.189544_bb1280","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.bbcan.2026.189544_bb1285","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb1290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb1295","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb1300","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb1305","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/2159-8290.CD-21-1508","article-title":"Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T-cell receptor lineages","volume":"12","author":"Wilson","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1310","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/s41467-023-43790-2","article-title":"Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening","volume":"14","author":"Ramos","year":"2023","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb1315","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat. Med."},{"issue":"7897","key":"10.1016\/j.bbcan.2026.189544_bb1320","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1325","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189544_bb1330","article-title":"IL-36gamma armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity","author":"Zuo","year":"2025","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189544_bb1335","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb1340","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int. J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1345","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb1350","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb1355","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189544_bb1360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189544_bb1365","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1370","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1375","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","article-title":"M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors","volume":"21","author":"Huo","year":"2023","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189544_bb1380","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41419-024-07267-4","article-title":"Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities","volume":"15","author":"Ziane-Chaouche","year":"2024","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189544_bb1385","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRPalpha enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb1390","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"7655","key":"10.1016\/j.bbcan.2026.189544_bb1395","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1400","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40820-020-00531-0","article-title":"Nanoparticle-loaded polarized-macrophages for enhanced tumor targeting and cell-chemotherapy","volume":"13","author":"Hou","year":"2020","journal-title":"Nano Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1405","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189544_bb1410","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189544_bb1415","article-title":"In vivo AAV-SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy","author":"Peng","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1420","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1425","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","article-title":"Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation","volume":"10","author":"Luo","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb1430","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 Costimulation augments CAR signaling in NK cells via the LCK\/CD3zeta\/ZAP70 Signaling Axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189544_bb1435","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189544_bb1440","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1445","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189544_bb1450","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104912","article-title":"Beyond CAR-T: engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy","volume":"214","author":"Zhang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1455","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189544_bb1460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1465","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb1470","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb1480","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb1485","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"issue":"26","key":"10.1016\/j.bbcan.2026.189544_bb1490","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2026.189544_bb1495","article-title":"Solid tumour cellular therapy - principles of toxicity management","volume":"25","author":"Julve","year":"2025","journal-title":"Immunooncol. Technol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189544_bb1500","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189544_bb1505","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the heart failure association (HFA) of the ESC and the ESC council of cardio-oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.bbcan.2026.189544_bb1510","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104471","article-title":"Advancements in tumor-infiltrating lymphocytes: historical insights, contemporary milestones, and future directions in oncology therapy","volume":"202","author":"Aizaz","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb1515","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189544_bb1520","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb1525","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1111\/cas.14993","article-title":"CAR-NK cell in cancer immunotherapy: a promising frontier","volume":"112","author":"Marofi","year":"2021","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189544_bb1530","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.molmed.2020.04.001","article-title":"The gut microbiota: emerging evidence in autoimmune diseases","volume":"26","author":"Zhang","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1535","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","article-title":"The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy","volume":"33","author":"Gopalakrishnan","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189544_bb1540","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2025.10.006","article-title":"Microbial modulation as a game changer: boosting immunotherapy efficacy in breast cancer","volume":"117","author":"Xia","year":"2025","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189544_bb1545","first-page":"0600","article-title":"Crosstalk between gut microbiota and cancer immunotherapy: present investigations and future perspective","volume":"8","author":"Tang","year":"2025","journal-title":"Research (Wash D C)"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb1550","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrmicro.2017.44","article-title":"Anticancer effects of the microbiome and its products","volume":"15","author":"Zitvogel","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189544_bb1555","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between drugs and the gut microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1560","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2895","article-title":"Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors","volume":"3","author":"Nomura","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"6371","key":"10.1016\/j.bbcan.2026.189544_bb1565","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.bbcan.2026.189544_bb1570","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"31","key":"10.1016\/j.bbcan.2026.189544_bb1575","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007630","article-title":"Recent advances in engineered materials for immunotherapy-involved combination cancer therapy","volume":"33","author":"Liang","year":"2021","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1580","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189544_bb1585","doi-asserted-by":"crossref","DOI":"10.1002\/cac2.70025","article-title":"Combating cancer immunotherapy resistance: a nano-medicine perspective","author":"Kong","year":"2025","journal-title":"Cancer Commun. (Lond.)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1590","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189544_bb1595","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","article-title":"Radiotherapy and immunotherapy: open questions and future strategies","volume":"8","author":"Pointer","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2026.189544_bb1600","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","article-title":"Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity","volume":"502","author":"Donlon","year":"2021","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189544_bb1605","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41590-024-01789-x","article-title":"A method for predicting drugs that can boost the efficacy of immune checkpoint blockade","volume":"25","author":"Xia","year":"2024","journal-title":"Nat. Immunol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:41:50Z","timestamp":1782031310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":321,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000168"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189544","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy-driven remodeling of the tumor immune microenvironment: Spatiotemporal heterogeneity and multidimensional dynamics","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189544"}}